000			01414 a2200361 4500
005			20250515233932.0
264		0	_c20100915
008			201009s 0 0 eng d
022			_a1532-8708
024	7		_a10.1053/j.seminoncol.2010.06.006 _2doi
040			_aNLM _beng _cNLM
100	1		_aMortimer, Joanne E
245	0	0	_aSafety considerations for use of bone-targeted agents in patients with cancer. _h[electronic resource]
260			_bSeminars in oncology _cJun 2010
300			_aS66-72 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aBone Density Conservation Agents _xadverse effects
650	0	4	_aBone Neoplasms _xprevention & control
650	0	4	_aBone and Bones _xdrug effects
650	0	4	_aDenosumab
650	0	4	_aDiphosphonates _xadverse effects
650	0	4	_aFever _xchemically induced
650	0	4	_aGastrointestinal Diseases _xchemically induced
650	0	4	_aHumans
650	0	4	_aKidney Diseases _xchemically induced
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aRANK Ligand _xadverse effects
700	1		_aPal, Sumanta Kumar
773	0		_tSeminars in oncology _gvol. 37 Suppl 1 _gp. S66-72
856	4	0	_uhttps://doi.org/10.1053/j.seminoncol.2010.06.006 _zAvailable from publisher's website
999			_c20021304 _d20021304